CSIMarket


Puma Biotechnology Inc.  (PBYI)
Other Ticker:  
 

Puma Biotechnology Inc.

PBYI's Fundamental analysis








Looking into Puma Biotechnology growth rates, revenue grew by 11.49 % in II. Quarter 2022 from the same quarter a year ago. Ranking at No. 1450

Major Pharmaceutical Preparations industry recorded growth of revenues by 10.65 %

Puma Biotechnology realized net income compared to net loss a year ago in II. Quarter 2022

More on PBYI's Growth


Puma Biotechnology
realized net loss in trailing twelve months.

Puma Biotechnology realized cash outflow of $ -1.03per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
91.55
PE TTM    
Company's Price to Sales ratio is at 0.52.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.02.


More on PBYI's Valuation
 
 Total Debt (Millions $) 98
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 7.05
 Tangible Book Value (Per Share $) -0.93

Puma Biotechnology
realized net loss in trailing twelve months.

Puma Biotechnology realized cash outflow of $ -1.03per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
91.55
PE TTM    
Company's Price to Sales ratio is at 0.52.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.02.

Puma Biotechnology Price to Book Ratio is at 5.49 lower than Indusry Avg. of 1250.71. and higher than S&P 500 Avg. of -0.01

More on PBYI's Valuation

  Market Capitalization (Millions $) 108
  Shares Outstanding (Millions) 45
  Employees -
  Revenues (TTM) (Millions $) 207
  Net Income (TTM) (Millions $) -35
  Cash Flow (TTM) (Millions $) -47
  Capital Exp. (TTM) (Millions $) -
  Total Debt (Millions $) 98
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ -
  Net Income/Employee(TTM) $ -
  Receivable Turnover Ratio (TTM) 7.05
  Tangible Book Value (Per Share $) -0.93

  Market Capitalization (Millions $) 108
  Shares Outstanding (Millions) 45
  Employees -
  Revenues (TTM) (Millions $) 207
  Net Income (TTM) (Millions $) -35
  Cash Flow (TTM) (Millions $) -47
  Capital Exp. (TTM) (Millions $) -


    PBYI's Profitability Comparisons
Puma Biotechnology achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2022 to 20.26 %.

Puma Biotechnology net profit margin of 15.74 % is currently ranking no. 28 in Major Pharmaceutical Preparations industry, ranking no. 64 in Healthcare sector and number 1109 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 2.01
  Total Debt to Equity (MRQ) 4.95
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 0.98
  Inventory Turnover Ratio (TTM) 6.79



Puma Biotechnology achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in II. Quarter 2022 to 20.26 %.

Puma Biotechnology net profit margin of 15.74 % is currently ranking no. 28 in Major Pharmaceutical Preparations industry, ranking no. 64 in Healthcare sector and number 1109 in S&P 500.

More on PBYI's Key Ratios



       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MAXD's Profile

Stock Price

MAXD's Financials

Business Description

Fundamentals

Charts & Quotes

MAXD's News

Suppliers

MAXD's Competitors

Customers & Markets

Economic Indicators

MAXD's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071